AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05298280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum appliance
Description: In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
Study NCT05298280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligners
Description: The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
Study NCT02310945 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Description: Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
Study NCT03085004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Gemcitabine admixture
Description: Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study NCT03085004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Gemcitabine admixture
Description: Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT04261101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test-enhanced learning
Description: Test-enhanced learning with short answers of questions regarding diabetes and adrenal
Study NCT04261101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test-enhanced learning
Description: Test-enhanced learning with short answers of questions regarding diabetes and adrenal
Study NCT04208958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VE800
Description: VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
Study NCT04208958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
Study NCT04208958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: Vancomycin is an antibiotic used to treat or prevent infection.
Study NCT03179423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose
Study NCT03179423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly IV repeated dose
Study NCT04355065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Traning with The Secret Trail of Moon
Description: Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
Study NCT04355065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Traning with Therapeutic Chess
Description: This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
Study NCT04355065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group.
Study NCT01680107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Study NCT01680107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01680107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behaviour therapy
Study NCT01680107 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive-behaviour therapy
Study NCT02075307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Study NCT02075307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05690490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection with circumferential incision
Description: The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
Study NCT05690490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
Study NCT03311750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
Study NCT01909479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Individualized once weekly dose of MOD-4023
Study NCT00682357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Lidocaine
Description: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
Study NCT00682357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Lidocaine
Description: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
Study NCT00682357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Lidocaine
Description: Placebo and lidocaine 20 mg
Study NCT00795548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: 5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given.
Study NCT03800342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: see arm/group description
Study NCT02390674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Comparison between ciclosporin and placebo
Study NCT02390674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02034175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SomnaPatch
Description: SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
Study NCT02034175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
Study NCT02093988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TXA
Study NCT02093988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous TXA
Study NCT02093988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Study NCT01962987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Study NCT01962987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Study NCT01962987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Study NCT02937857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment only
Description: standard treatment， such as antiasthmatic,expectorant,antipyretic
Study NCT02937857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment+Xiyanping injection
Description: standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
Study NCT03455868 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study NCT01801176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
Study NCT01909479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once weekly administration of placebo
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl prednisolone
Study NCT01773616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl prednisolone
Study NCT00631969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT (STAXYN, BAY38-9456)
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
Study NCT00631969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study NCT01944462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Pneumococcal Vaccine Program (PPVP)
Description: 1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
Study NCT03815955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Sedentary Behaviour Modelling
Description: Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
Study NCT05327309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT05327309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT01497002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
Study NCT01497002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
Study NCT01497002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human stem cells
Description: Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
Study NCT02483715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (rabeprazole, amoxicillin)
Description: High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
Study NCT02483715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
Description: Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
Study NCT02994576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg administered I.V. once
Study NCT00417235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Sponge (Biopatch TM)
Description: dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
Study NCT00417235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day catheter dressing frequency
Description: dressing changes every 7 days versus every classical change every 3 days
Study NCT02067104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Study NCT02067104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Study NCT02358863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
Study NCT02858531 — intervention group
Intervention type: OTHER
Intervention: data retrieval
Description: data retrieval with the Hospital Information System
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administration according to investigator's discretion
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administration according to investigator's discretion
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administration according to investigator's discretion
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: Administration according to investigator's discretion
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administration according to investigator's discretion
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: Administration 30 mg/m² q21
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Administration 1.1 mg/m² q21
Study NCT03690739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administration according to investigator's discretion
Study NCT01684644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme
Study NCT01684644 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Study NCT03404908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
Study NCT03404908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QL (quadratus lumborum block)
Description: the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
Study NCT03404908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
Study NCT03404908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
Study NCT03404908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT03404908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metamizole
Description: Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
Study NCT00212030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicorandil
Description: (0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
Study NCT00212030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control
Study NCT03418298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation group
Description: Subjects will performed an internet-based exercise program before surgery
Study NCT03557151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
Study NCT03557151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdisciplinary Care-In Person & Telehealth
Description: TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
Study NCT01548703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 100 mg or matching placebo administered once daily for 7 days
Study NCT01548703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
Study NCT02132325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
Study NCT01914744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg/day PO
Study NCT01914744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: entecavir 0.5 mg/day PO